IFNA1 and systemic lupus erythematosus: In the field of immunology and rheumatology, the literature and clinical practice data converge in describing a pattern of hyperactivation of the IFN-I pathway that is common to several systemic diseases (e.g., SLE, Sjögren’s syndrome, systemic sclerosis, inflammatory myopathies), with a significant proportion of “IFN-high” patients.